The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
Open accessAbstract
BACKGROUND: Cytomegalovirus (CMV) infection remains a common complication after allogeneic hematopoietic-cell transplantation. Letermovir is an antiviral drug that inhibits the CMV-terminase complex. METHODS: In this phase 3, double-blind trial, we randomly assigned CMV-seropositive transplant recipients, 18 years of age or older, in a 2:1 ratio to receive letermovir or placebo, administered orally or intravenously, through week 14 after transplantation; randomization was stratified according to trial site and CMV disease risk. Letermovir was administered at a dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine). Patients in whom clinically significant CMV infection (CMV disease or CMV viremia leading to preemptive treatment) developed discontinued the trial regimen and received anti-CMV treatment. The primary end point was the proportion of patients, among patients without detectable CMV DNA at randomization, who had clinically significant CMV infection through week 24 after transplantation. Patients who discontinued the trial or had missing end-point data at week 24 were imputed as having a primary end-point event. Patients were followed through week 48 after transplantation. RESULTS: From June 2014 to March 2016, a total of 565 patients underwent randomization and received letermovir or placebo beginning a median of 9 days after transplantation. Among 495 patients with undetectable CMV DNA at randomization, fewer patients in the letermovir group than in the placebo group had clinically significant CMV infection or were imputed as having a primary end-point event by week 24 after transplantation (122 of 325 patients [37.5%] vs. 103 of 170 [60.6%], P<0.001). The frequency and severity of adverse events were similar in the two groups overall. Vomiting was reported in 18.5% of the patients who received letermovir and in 13.5% of those who received placebo; edema in 14.5% and 9.4%, respectively; and atrial fibrillation or flutter in 4.6% and 1.0%, respectively. The rates of myelotoxic and nephrotoxic events were similar in the letermovir group and the placebo group. All-cause mortality at week 48 after transplantation was 20.9% among letermovir recipients and 25.5% among placebo recipients. CONCLUSIONS: Letermovir prophylaxis resulted in a significantly lower risk of clinically significant CMV infection than placebo. Adverse events with letermovir were mainly of low grade. (Funded by Merck; ClinicalTrials.gov number, NCT02137772 ; EudraCT number, 2013-003831-31 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Definitions of Cytomegalovirus Infection and Disease in Transplant Recipients
Ljungman, P., Griffiths, P., & Paya, C. (2002) · Clinical Infectious Diseases · doi:10.1086/339329 · Cited by 1,234
Self-citationComparative analysis of two rates
Miettinen, O., & Nurminen, M. (1985) · Statistics in Medicine · doi:10.1002/sim.4780040211 · Cited by 1,110
Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease
Kimberlin, D. W., Jester, P. M., Sánchez, P. J., Ahmed, A., Arav-Boger, R., Michaels, M. G., Ashouri, N., Englund, J. A., Estrada, B., Jacobs, R. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1404599 · Cited by 827
Risk Factors for Cytomegalovirus Infection after Human Marrow Transplantation
Meyers, J. D., Flournoy, N., & Donnall Thomas, E. (1986) · Journal of Infectious Diseases · doi:10.1093/infdis/153.3.478 · Cited by 776
Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow Transplant
Goodrich, J. M., Bowden, R. A., Fisher, L., Keller, C., Schoch, G., & Meyers†, J. D. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-3-199302010-00003 · Cited by 650
Niemi, M., Pasanen, M. K., & Neuvonen, P. J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002857 · Cited by 633
Goodrich, J. M., Mori, M., Gleaves, C. A., Du Mond, C., Cays, M., Ebeling, D. F., Buhles, W. C., DeArmond, B., & Meyers, J. D. (1991) · New England Journal of Medicine · doi:10.1056/nejm199112053252303 · Cited by 599
Teira, P., Battiwalla, M., Ramanathan, M., Barrett, A. J., Ahn, K. W., Chen, M., Green, J. S., Saad, A., Antin, J. H., Savani, B. N., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679639 · Cited by 553
Self-citationNonbacterial Pneumonia After Allogeneic Marrow Transplantation: A Review of Ten Years' Experience
Meyers, J. D., Flournoy, N., & Thomas, E. D. (1982) · Clinical Infectious Diseases · doi:10.1093/clinids/4.6.1119 · Cited by 522
Humar, A., Lebranchu, Y., Vincenti, F., Blumberg, E. A., Punch, J. D., Limaye, A. P., Abramowicz, D., Jardine, A. G., Voulgari, A. T., Ives, J., et al. (2010) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2010.03074.x · Cited by 504
Self-citationLetermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation
Chemaly, R. F., Ullmann, A. J., Stoelben, S., Richard, M. P., Bornhäuser, M., Groth, C., Einsele, H., Silverman, M., Mullane, K. M., Brown, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1309533 · Cited by 378
Self-citationCMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation
Marty, F. M., Winston, D. J., Rowley, S. D., Vance, E., Papanicolaou, G. A., Mullane, K. M., Brundage, T. M., Robertson, A. T., Godkin, S., Momméja-Marin, H., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303688 · Cited by 374
Self-citationMarty, F. M., Ljungman, P., Papanicolaou, G. A., Winston, D. J., Chemaly, R. F., Strasfeld, L., Young, J.-A. H., Rodriguez, T., Maertens, J., Schmitt, M., et al. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70024-x · Cited by 350
Self-citationGoldner, T., Hewlett, G., Ettischer, N., Ruebsamen‐Schaeff, H., Zimmermann, H., & Lischka, P. (2011) · Journal of Virology · doi:10.1128/jvi.05265-11 · Cited by 336
Winston, D. J., Young, J.-A. H., Pullarkat, V., Papanicolaou, G. A., Vij, R., Vance, E., Alangaden, G. J., Chemaly, R. F., Petersen, F., Chao, N., et al. (2008) · Blood · doi:10.1182/blood-2007-11-121558 · Cited by 245
Self-citationIn Vitro and In Vivo Activities of the Novel Anticytomegalovirus Compound AIC246
Lischka, P., Hewlett, G., Wunberg, T., Baumeister, J., Paulsen, D., Goldner, T., Ruebsamen-Schaeff, H., & Zimmermann, H. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01596-09 · Cited by 240
Green, M. L., Leisenring, W., Stachel, D., Pergam, S. A., Sandmaier, B. M., Wald, A., Corey, L., & Boeckh, M. (2012) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2012.05.015 · Cited by 165
Self-citationPreemptive Therapy in Immunocompromised Hosts
Rubin, R. H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104113241509 · Cited by 157
Marty, F. M., Porter, J., Browne, S., Schwarzberg, T., Ho, V. T., Bassett, I. V., Koreth, J., Alyea, E. P., Soiffer, R. J., Cutler, C. S., et al. (2007) · Blood · doi:10.1182/blood-2007-01-069294 · Cited by 142
Self-citationAmundsen, R., Christensen, H., Zabihyan, B., & Åsberg, A. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.032268 · Cited by 135
Human cytomegalovirus terminase as a target for antiviral chemotherapy
Bogner, E. (2002) · Reviews in Medical Virology · doi:10.1002/rmv.344 · Cited by 112
Borst, E. M., Kleine-Albers, J., Gabaev, I., Babić, M., Wagner, K., Binz, A., Degenhardt, I., Kalesse, M., Jonjić, S., Bauerfeind, R., et al. (2012) · Journal of Virology · doi:10.1128/jvi.01955-12 · Cited by 99
Reefschlaeger, J. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.6.757 · Cited by 94
The prevention of infection post-transplant: the role of prophylaxis, preemptive and empiric therapy
Marty, F. M., & Rubin, R. H. (2005) · Transplant International · doi:10.1111/j.1432-2277.2005.00218.x · Cited by 65
Self-citationRazonable, R. R., & Blumberg, E. A. (2015) · Transplant Infectious Disease · doi:10.1111/tid.12447 · Cited by 34
Self-citation
Cited by
Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta‐analysis
Zuhair, M., Smit, G. S. A., Wallis, G., Jabbar, F., Smith, C., Devleesschauwer, B., & Griffiths, P. (2019) · Reviews in Medical Virology · doi:10.1002/rmv.2034 · Cited by 889
Razonable, R. R., & Humar, A. (2019) · Clinical Transplantation · doi:10.1111/ctr.13512 · Cited by 753
Aiello, A., Farzaneh, F., Candore, G., Caruso, C., Davinelli, S., Gambino, C. M., Ligotti, M. E., Zareian, N., & Accardi, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02247 · Cited by 693
Pathogenesis of human cytomegalovirus in the immunocompromised host
Griffiths, P., & Reeves, M. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00582-z · Cited by 610
for the Infectious Diseases Working Party, E. B. M. T., Styczyński, J., Tridello, G., Koster, L., Iacobelli, S., van Biezen, A., van der Werf, S., Mikulska, M., Gil, L., Cordonnier, C., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0624-z · Cited by 351
Self-citation
Metadata
- Authors
- Marty, F. M., Ljungman, P., Chemaly, R. F., Maertens, J., Dadwal, S. S., Duarte, R. F., Haider, S., Ullmann, A. J., Katayama, Y., Brown, J., Mullane, K. M., Boeckh, M., Blumberg, E. A., Einsele, H., Snydman, D. R., Kanda, Y., DiNubile, M. J., Teal, V. L., Wan, H., Murata, Y., Kartsonis, N. A., Leavitt, R. Y., & Badshah, C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-12-21
- Volume
- 377
- Issue
- 25
- Pages
- 2433-2444
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2771598353
- Cited by
- 1,238
- References
- 25
- FWCI
- 67.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.